Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2019 08:00 ET | Source: Replimune Group Inc

Replimune to Present at 2019 Wedbush PacGrow Healthcare Conference

WOBURN, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
June 28, 2019 08:00 ET | Source: Replimune Group Inc

Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and Provides Corporate Update

RP1: Initiated Phase 2 part of Phase 1/2 clinical trial of RP1 in combination with nivolumab in the U.S. and the U.K. RP1: Initial Data from Phase 1 part of Phase 1/2 clinical trial expected to be...
June 01, 2019 09:00 ET | Source: Replimune Group Inc

Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab

WOBURN, Mass., June 01, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
May 30, 2019 08:00 ET | Source: Replimune Group Inc

Replimune to Present at Upcoming Investor Conferences

WOBURN, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
May 16, 2019 07:00 ET | Source: Replimune Group Inc

Replimune Announces Poster Presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

WOBURN, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
April 01, 2019 07:00 ET | Source: Replimune Group Inc

Replimune Announces Presentation at the American Association for Cancer Research Annual Meeting 2019

WOBURN, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
February 14, 2019 08:00 ET | Source: Replimune Group Inc

Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update

RP1: Completed Single Agent Enrollment in Part 1 Portion of Phase 1/2 Clinical Trial in the UK;Part 1 Enrollment Opened for Combination with Nivolumab in Patients with Solid Tumors in the US RP1:...
February 07, 2019 08:00 ET | Source: Replimune Group Inc

Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today...
January 03, 2019 08:00 ET | Source: Replimune Group Inc

Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference

RP1: U.S. Enrollment Opened for Phase 1/2 Clinical Trial in Combination with Nivolumab in Patients with Solid Tumors RP1: Randomized Controlled Phase 2 Clinical Trial Alone and in Combination with...
December 20, 2018 08:00 ET | Source: Replimune Group Inc

Replimune to Present at the 37th Annual J.P.Morgan Healthcare Conference

WOBURN, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today...